Brief: Apyx Medical Corporation Receives FDA 510(K) Clearance For Use Of Renuvion
28/04/2023 14:26
April 28 (Reuters) - Apyx Medical Corp APYX.O :
* APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR
THE
USE OF RENUVION® FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES
FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURING
Source text for Eikon: ID:nBw3l9SFXa
Further company coverage: APYX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apyx Medical
See all newsBrief: Apyx Medical - Appoints Stavros Vizirgianakis As Executive Chairman Effective June 11, 2026
Brief: Apyx Medical Corporation Receives Expanded FDA 510(K) Clearance Adding Power Liposuction Capability To AYON Body Contouring System™
Apyx Medical Q1 revenue beats estimates, outlook raised
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength